Published in Healthcare (Basel) on December 20, 2013
Multicenter Selective Lymphadenectomy Trial II (MSLT-II) | NCT00297895
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer (2005) 4.55
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer (2005) 3.02
Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer (2005) 2.63
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet (2011) 2.36
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol (2013) 2.34
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev (2003) 2.08
Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol (2007) 1.58
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg (2003) 1.58
Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol (2010) 1.48
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol (2012) 1.44
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol (2012) 1.32
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol (2012) 1.27
Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol (2012) 1.24
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget (2013) 1.20
Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg (2002) 1.15
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev (2013) 1.09
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol (1995) 1.05
Targeting NRAS in melanoma. Cancer J (2012) 1.00
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Adjuvant therapy of melanoma. Cancer J (2007) 0.98
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol (2013) 0.87
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol (2012) 0.82
Early detection of melanoma improves survival. Practitioner (2009) 0.79
Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol (2003) 0.79
De novo melanoma and melanoma arising from pre-existing nevus: in vivo morphologic differences as evaluated by confocal microscopy. J Am Acad Dermatol (2011) 0.78
Update on PEG-interferon α-2b as adjuvant therapy in melanoma. Anticancer Res (2012) 0.78
Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma. Report of two cases. Arch Dermatol (1983) 0.77
Ocular melanoma. Surg Clin North Am (2003) 0.76